<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907270</url>
  </required_header>
  <id_info>
    <org_study_id>69770</org_study_id>
    <nct_id>NCT00907270</nct_id>
  </id_info>
  <brief_title>Supplementation With Vitamin D Improves Leptin Resistance</brief_title>
  <official_title>Effect of Vitamin D Supplementation on Leptin Resistance, Hunger, Body Weight and Resting Energy Expenditure in Obese Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mexican National Institute of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mexican National Institute of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants will be randomly assigned in one of two groups. Group A: oral supplementation
      with 4,000 IU of vitamin D (cholecalciferol). Group B: oral supplementation with 400 IU of
      vitamin D (cholecalciferol). Both treatments will be consumed daily for 6 months.

      Outcomes will be evaluated at baseline, three and six months. Variables related to leptin
      resistance will be evaluated.

      The main hypothesis is that vitamin D will diminish leptin resistance in overweight and obese
      women. If the hypothesis is confirmed, women will show a reduction in the Resting energy
      expenditure: serum Leptin ratio (REE: Leptin ratio), as well as a reduction of hunger, body
      weight, body and abdominal fat and an increase in resting energy expenditure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study subjects will get dietary advice and physical activity counseling. At the end of the
      study, participants with suboptimal vitamin D levels (&lt;80 nmol/L 25-OH-D) will receive
      treatment to normalize their vitamin D status.

      Variables related to leptin resistance like resting metabolic expenditure, hunger, body
      weight and human body fat will be assessed. Outcomes will include, glucose, insulin,
      C-reactive protein, inflammatory interleukins (IL-6 &amp; TNF-α) and non-inflammatory
      interleukins (IL-10 &amp; TGF-β-1).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of leptin resistance: (resting energy expenditure: leptin ratio) before and after (3 and 6 months) supplementation with vitamin D3 (cholecalciferol) 4,000 or 400 IU/day.</measure>
    <time_frame>basal, third and sixth month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of vitamin D supplementation (25-OH-D): hunger, body weight, energy intake, resting energy expenditure, and body fat, improvement on low intensity chronic inflammation, SOCS-3 expression and JAK2/STAT3 signal.</measure>
    <time_frame>Basal, third and sixth month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol: 400 IU/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D (Cholecalciferol: 400 IU/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholecalciferol 4000 IU/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: (n=50) Each subject will be evaluated after supplementation during six months with Vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Cholecalciferol: 4,000 IU/day and 400 IU/day</description>
    <arm_group_label>Cholecalciferol: 400 IU/day</arm_group_label>
    <arm_group_label>Cholecalciferol 4000 IU/day</arm_group_label>
    <other_name>Cholecalciferol supplementation (400 IU and 4000 IU)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI: 25-29.9

          -  Serum vitamin D levels: 20-80 nmol/L (25-OH-D)

        Exclusion Criteria:

          -  Liver disease

          -  Kidney disease

          -  Diabetes mellitus

          -  Malignity

          -  Any kind of hormonal disorder

          -  Medication that modify hunger/satiety answer and those medications that alter -the
             glucose/insulin metabolism

          -  Subjects with diet treatment to lose weight
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Flores-Aldana, MsC</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of public Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mario Flores-Aldana, MsC</last_name>
    <phone>(52)777-329-30-00</phone>
    <phone_ext>7451</phone_ext>
    <email>mflores@insp.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nayeli Macías-Morales, MsC</last_name>
    <phone>(52)777-329-30-00</phone>
    <phone_ext>7451</phone_ext>
    <email>nmacias@insp.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institute of Social Insurance</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62450</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2009</study_first_submitted>
  <study_first_submitted_qc>May 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2009</study_first_posted>
  <last_update_submitted>May 20, 2009</last_update_submitted>
  <last_update_submitted_qc>May 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mario Flores-Aldana</name_title>
    <organization>National Institute of Public Health</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

